UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti-CD19 CAR-T therapy: a case report

Mackenzie, Strachan; Shafat, Manar; Roddy, Harriet; Hyare, Harpreet; Neill, Lorna; Marzolini, Maria AV; Gilhooley, Michael; ... Roddie, Claire; + view all (2021) Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti-CD19 CAR-T therapy: a case report. EJHaem , 2 (4) pp. 848-853. 10.1002/jha2.274. Green open access

[thumbnail of eJHaem - 2021 - Mackenzie - Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following.pdf]
Preview
PDF
eJHaem - 2021 - Mackenzie - Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following.pdf - Published Version

Download (2MB) | Preview

Abstract

Progressive multifocal leukoencephalopathy (PML) is an opportunistic brain infection with few treatment options and poor survival when reversal of the underlying immune dysfunction is not achievable. JC polyomavirus reactivation resulting in PML can rarely complicate chimeric antigen receptor T-cell (CAR-T) therapy. We describe successful treatment of PML with Programmed death-1 (PD-1) blockade using pembrolizumab, 4 months following axicabtagene ciloleucel. Radiological features of immune reconstitution inflammatory syndrome without clinical deterioration were seen. Evidence of anti-viral immune reconstitution by in vitro detection of JC-specific T-cells and sustained neurological recovery in this patient suggest PD-1 blockade may be an effective treatment approach for PML post-CAR-T.

Type: Article
Title: Pembrolizumab for the treatment of progressive multifocal leukoencephalopathy following anti-CD19 CAR-T therapy: a case report
Location: United States
Open access status: An open access version is available from UCL Discovery
DOI: 10.1002/jha2.274
Publisher version: https://doi.org/10.1002/jha2.274
Language: English
Additional information: © 2021 The Authors. eJHaem published by British Society for Haematology and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
Keywords: checkpoint inhibition, chimeric antigen receptor T‐ cell, herald lesion, immune reconstitution inflammatory syndrome, pembrolizumab, progressive multifocal leukoencephalopathy
UCL classification: UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute > Research Department of Pathology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Cancer Institute
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Neurodegenerative Diseases
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > UCL Queen Square Institute of Neurology > Department of Neuromuscular Diseases
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Brain Sciences > Institute of Ophthalmology
URI: https://discovery-pp.ucl.ac.uk/id/eprint/10153380
Downloads since deposit
17,708Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item